Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
What is pinealon?
Pinealon is a short synthetic peptide (a tripeptide) developed within the “peptide bioregulator” research program. It is grouped with other short neuroactive peptides studied for neuroprotective properties (Umnov et al., 2013).
What the research examined
A review comparing neuroprotective peptides discusses two groups: polypeptide complexes (such as cortexin and cerebrolysin) and short peptides (such as semax, kortagen, and pinealon). It summarizes reported clinical use in elderly and aging populations and describes proposed cellular and molecular mechanisms of neuroprotective activity (Umnov et al., 2013).
How it is thought to work
Short peptide bioregulators like pinealon are proposed to influence gene-expression and cell-protective pathways in neural tissue, which is the basis for their study in age-related neuroscience (Umnov et al., 2013).
The limits of the current evidence
- The literature is concentrated in specific research groups and is limited; robust independent controlled trials are sparse.
- Pinealon is not an approved medicine; this material is for laboratory research use only.
References
According to PubMed:
- Umnov RS, Lin’kova NS, Khavinson VKh. Neuroprotective effects of peptide bioregulators in people of various ages. Adv Gerontol. 2013. PMID:24738258
